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multiple aliquots were stored at exactly 1 h after collection at 80 C
pendinganalysis.Asdemonstratedbyothers, concentrationandactivity
of MMP is stable during long term storage at80 C.1
Assays
Plasma levels of MMP- 2, -9 and TIMP-1 were determined
by means of a commercially available enzyme linked immunosor-
bent assay (GE Healthcare/lifesciences, Upssala, Sweden) according
to themanufacturer’s guidelines and were determined in duplicate.
Duplicates with less than 10% within assay variation in concentra-
tion were accepted and means were determined for further anal-
ysis. The between-assay variation (7% for MMP-2, 10% for both
MMP-9 and TIMP-1) was determined by the manufacturer.Yours faithfully,Reference
1 Sulik, A., Wojtkowska, M. & Oldak, E. 2008. Preanalytical factors affecting the
stability of matrix metalloproteinase-2 concentrations in cerebrospinal ﬂuid.
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doi:10.1016/j.ejvs.2012.02.001Factors Affecting Amputation-free Survival Rates in Critical
Limb IschemiaDOI of original article: 10.1016/j.ejvs.2012.01.034.First of all, we would like to congratulate the authors upon their
study investigating the factors affecting amputation-free survival in
the patients with critical limb ischemia (CLI).1 Cilostazol is not
mentioned among the medical treatment protocols provided to the
patients in the article, whereas there are a number of studies report-
ing lower amputation rates upon cilostazol administration in the
patients with CLI who had undergone endovascular intervention.2,3
Moreover, cilostazol administration was also documented to pull
down the amputation rates even in the cases with CLI in whom no
intervention was undertaken.4,5 Therefore, we believe the
amputation-free survival rates emerging in the present study would
be more accurate if an evaluation is made by taking into consider-
ation that cilostazol is not used in the study. Likewise, we also noted
in the study that extra-anatomic by-pass (EAB) procedure is imple-
mented in 3 out of 15 patients undergoing revascularization due to
ischemic pain. If EAB was undertaken in these patients during the
ﬁrst surgical intervention, what was the actual reason behind? If
EAB procedurewas preferred in these patients owing to the presence
of previous surgical operation, do you think the previous history ofvascular surgery had an impact on the amputation rates?We believe
that evaluation of the present study would be comprehended much
more thoroughly by keeping all the aforementioned issues in mind.
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doi:10.1016/j.ejvs.2012.01.034Response to Letter to the Editor: Factors Affecting Amputation-
Free Survival Rates in Critical Limb IschemiaWe appreciate the comments concerning our article on
amputation-free survival in patients with CLI.
We collected our data in 2004 and 2005. At that time, cilostazol
was not yet approved for treatment of patients with PAD, in
Germany. Therefore, we do not have any data concerning the inﬂu-
ence of cilostazol on amputation-free survival in our study popula-
tion. Nevertheless, we agree with the authors that cilostazol mighth-
a-
ve
